Display options
Cite
Fathi-Moghaddam H, Shafiee Ardestani M, Saffari M, et al. The selective cyclooxygenase-2 inhibitor, the compound 11b improves haloperidol induced catatonia by enhancing the striatum dopaminergic neurotransmission. Iran J Pharm Res. 2010;9(4):387-93
Fathi-Moghaddam, H., Shafiee Ardestani, M., Saffari, M., Jabbari Arabzadeh, A., & Elmi, M. (2010). The selective cyclooxygenase-2 inhibitor, the compound 11b improves haloperidol induced catatonia by enhancing the striatum dopaminergic neurotransmission. Iranian journal of pharmaceutical research : IJPR, 9(4), 387-93.
Fathi-Moghaddam, Hadi, et al. "The selective cyclooxygenase-2 inhibitor, the compound 11b improves haloperidol induced catatonia by enhancing the striatum dopaminergic neurotransmission." Iranian journal of pharmaceutical research : IJPR vol. 9,4 (2010): 387-93.
Fathi-Moghaddam H, Shafiee Ardestani M, Saffari M, Jabbari Arabzadeh A, Elmi M. The selective cyclooxygenase-2 inhibitor, the compound 11b improves haloperidol induced catatonia by enhancing the striatum dopaminergic neurotransmission. Iran J Pharm Res. 2010;9(4):387-93. PMID: 24381603; PMCID: PMC3870062.
Copy Download .nbib Format: NLM
Share it on

Iran J Pharm Res. 2010;9(4):387-93.

The selective cyclooxygenase-2 inhibitor, the compound 11b improves haloperidol induced catatonia by enhancing the striatum dopaminergic neurotransmission.

Iranian journal of pharmaceutical research : IJPR

Hadi Fathi-Moghaddam, Mehdi Shafiee Ardestani, Mostafa Saffari, Ali Jabbari Arabzadeh, Mitra Elmi

Affiliations

  1. Depattment of Physiology and Physiology Research Center, School of Medicine, Jondishapour University of Medical Sciences, Ahwaz, Iran.
  2. Department of Pharmacology, Razi institute for drug research, College of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  3. Department of Medicinal Chemistry and Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran .
  4. Department of Pharmaceutics, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

PMID: 24381603 PMCID: PMC3870062

Abstract

A substantial amount of evidence has proposed an important role for Cyclooxygenase-2 (COX-2) enzyme in brain diseases and affiliate disorders. The purpose of this research was studying the effects of COX-2 selective inhibition on haloperidol-induced catatonia in an animal model of drug overdose and Parkinson's disease (PD). In this study, the effect of acute and Sub-chronic oral administration of a new selective COX-2 inhibitor, i.e. the compound 11b or 1-(Phenyl)-5-(4-methylsulfonylphenyl)-2-ethylthioimidazole, in a dosage of 2, 4 and 8 mg/kg on haloperidol-induced catatonia was evaluated and compared to the standard drug scopolamine (1 mg/kg) by microanalysis of Striatum dopaminergic neurotransmission. The results showed a very high potency for 11b in improving the catalepsy by enhancing the dopaminergic neurotranmission (p < 0.05). In addition, statistical analysis showed the dose- and time-dependent behavior of the observed protective effect of 11b against the haloperidol-induced catatonia and enhancement of the dopaminergic neurotransmission. These findings are additional pharmacological data that suggest the effectiveness of COX-2 inhibition in treatment of schizophreny-associated rigidity.

Keywords: Catalepsy; Compound 11b; Dopaminergic neurotransmission; Nigrostriatal

References

  1. Neuropharmacology. 2003 Jun;44(8):1100-6 - PubMed
  2. Neuropharmacology. 1995 Jan;34(1):97-9 - PubMed
  3. Braz J Med Biol Res. 2003 Feb;36(2):239-45 - PubMed
  4. Eur J Pharmacol. 2002 May 24;444(1-2):69-74 - PubMed
  5. Basic Clin Pharmacol Toxicol. 2008 Oct;103(4):293-6 - PubMed
  6. Ann Neurol. 2003 Nov;54(5):599-604 - PubMed
  7. Br J Pharmacol. 2002 May;136(2):193-200 - PubMed
  8. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1130-8 - PubMed
  9. Neurosci Lett. 2000 Aug 11;289(3):201-4 - PubMed
  10. Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5473-8 - PubMed
  11. Bioorg Med Chem. 2007 Mar 1;15(5):1976-82 - PubMed
  12. Neuropharmacology. 2005 Aug;49(2):135-43 - PubMed
  13. Brain Res. 2003 Apr 11;968(2):273-6 - PubMed
  14. J Neurochem. 2005 Nov;95(4):1078-90 - PubMed
  15. Brain Res. 1994 Nov 14;663(2):237-43 - PubMed

Publication Types